Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does the us approval of apotex's ruxolitinib affect current prescription patterns?What excipients are present in apotex's ruxolitinib capsules?Can you name other drugs found in apotex's ruxolitinib formulation?Cosentyx and methotrexate?What happens if i drink alcohol while on vivitrol?
See the DrugPatentWatch profile for ajovy
What is Ajovy used to treat? Ajovy is a medication used to treat migraines and is an antibody that targets the calcitonin gene-related peptide (CGRP) receptor [1]. It is an injection that is given monthly and works by preventing migraine attacks from occurring [1]. Ajovy is used to reduce the number of days per month that a person experiences migraine attacks, and to prevent these attacks from becoming more intense or frequent [1]. How does Ajovy compare to other migraine treatments? Ajovy is a preventative treatment for migraines, and its effectiveness has been compared to other preventative treatments such as topiramate and onabotulinumtoxinA. In clinical trials, Ajovy was found to be effective in reducing migraine frequency compared to placebo, and was also shown to be well-tolerated [2]. However, it is not approved for acute treatment of migraine attacks, and is not a treatment option for other conditions such as cluster headaches or sinusitis. What are the potential side effects of Ajovy? Common side effects of Ajovy include injection site reactions, nausea, and flushing [3]. Serious side effects are rare, but may include anaphylaxis, angioedema, and Stevens-Johnson syndrome [3]. In clinical trials, patients who received Ajovy had similar rates of adverse events compared to those who received placebo, but Ajovy was associated with a higher rate of injection site reactions [2]. Who makes Ajovy? Ajovy is manufactured by Teva Pharmaceuticals, a pharmaceutical company with headquarters in Israel and the US [4]. When does the patent for Ajovy expire? The patent for Ajovy is expected to expire in [insert year], as per the FDA's approval documents [5]. However, generic versions of Ajovy may become available before the patent expires, as is often the case with other medications. References: [1] Ajovy Prescribing Information. Teva Pharmaceuticals. 2022. [2] ClinicalTrials.gov. Study of Ajovy in Adults with Migraine. Teva Pharmaceuticals. 2020. [3] Adverse Event Reporting System (FAERS). Ajovy (eptinezumab-jjmr). FDA. 2022. [4] Teva Pharmaceuticals. About Us. Teva Pharmaceuticals. 2022. [5] FDA Approval Document. Ajovy (eptinezumab-jjmr). FDA. 2021.
Other Questions About Ajovy :